Company intelligence / Profile preview

Crystalys Therapeutics

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Crystalys Therapeutics' lead asset is dotinurad, a small molecule URAT1 inhibitor acquired from Urica Therapeutics. It is in Phase 3 clinical development for the treatment of gout, targeting reduction of serum uric acid. No clinical results are yet published by Crystalys; prior clinical data exists from Urica and Fuji Yakuhin Co. Ltd.

Therapeutic areas: Rheumatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Urica Therapeutics

Beyond the preview

Go deeper on Crystalys Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crystalys Therapeutics.

Explore the full profile